Kiniksa Pharmaceuticals International (KNSA) Shares Outstanding (2017 - 2026)

Kiniksa Pharmaceuticals International (KNSA) has reported Shares Outstanding (Entity) for 10 consecutive years, with $156.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Shares Outstanding (Entity) rose 5.31% year-over-year to $156.0 million; the trailing twelve-month figure through Jun 2026 stood at $156.0 million (up 5.31% YoY), and the FY2025 full-year result was $152.8 million, up 5.19% from the prior year.
• Shares Outstanding (Entity) advanced to $156.0 million in Q2 2026 per KNSA's latest filing, from $153.6 million in the prior quarter.
• Across five years, Shares Outstanding (Entity) topped out at $156.0 million in Q2 2026 and bottomed at $137.4 million in Q1 2024.
• Historically, Shares Outstanding (Entity) has averaged $144.2 million across 5 years, with a median of $141.7 million in 2023.
• The sharpest annual moves came in 2024 and 2025: Shares Outstanding (Entity) declined 1.7% in 2024, then increased 6.12% in 2025.
• Over 5 years, Shares Outstanding (Entity) stood at $139.5 million in 2022, then advanced by 1.17% to $141.1 million in 2023, then advanced by 2.99% to $145.3 million in 2024, then climbed by 5.19% to $152.8 million in 2025, then climbed by 2.08% to $156.0 million in 2026.
• According to Business Quant data, Shares Outstanding (Entity) over the past three periods registered $156.0 million, $153.6 million, and $152.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.